Showing 3701-3710 of 5621 results for "".
- Sydnexis Appoints Erin Horn as Vice President, Head of Market Accesshttps://modernod.com/news/sydnexis-names-erin-horn-as-vice-president-head-of-market-access/2482071/Sydnexis has announced the appointment of Erin Horn as Vice President, Head of Market Access. Ms. Horn will lead Sydnexis’ market access, pricing, contracting, and go-to-market strategies. With 25 years of industry experience, Ms. Horn has a track record of commercial success
- iuvo BioScience Acquires Promedica International to Expand Ophthalmic Clinical CRO Serviceshttps://modernod.com/news/iuvo-bioscience-acquires-promedica-international-to-expand-ophthalmic-clinical-cro-services/2482070/Partner Research Organization iuvo BioScience announced it has acquired Promedica International (PMI), an ophthalmology-focused clinical CRO. Financial terms of the deal were not disclosed. The companies say the combined organization will support all aspects of opht
- Inflammasome Therapeutics Announces First Patient Dosed in Phase 1 DME Study of the Dual Inflammasome Inhibitor K8https://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-phase-1-dme-study-of-the-dual-inflammasome-inhibitor-k8/2482069/Inflammasome Therapeutics announced the first patient has been dosed in a phase 1 study of a novel compound in the treatment of diabetic macular edema (DME). The 24-week study (ClinicalTrials.gov ID NCT05699759) is designed to assess safety and initial evidence of efficacy. Th
- LumiThera Initiates EUROLIGHT Registry Study to Evaluate Long-Term Benefits of PBM Using the Valeda for Dry AMDhttps://modernod.com/news/lumithera-initiates-eurolight-registry-study-to-evaluate-long-term-benefits-of-pbm-using-the-valeda-light-delivery-system-for-dry-amd/2482067/LumiThera announced the initiation of the largest PBM trial ever conducted in patients with dry age-related macular degeneration (AMD). A global registry data collection from patients treated with PBM using the Valeda Light Delivery System has been established with Dendrite Clinica
- Rayner Acquires This AG, Maker of Sophi Phaco Machineshttps://modernod.com/news/rayner-acquires-this-ag-maker-of-sophi-phaco-machines/2482064/Rayner announced that it has entered into a definitive agreement to acquire Swiss-based This AG, the inventor, developer and manufacturer of Sophi phaco emulsification machines. Financial terms of the deal were not disclosed. The acquisition marks a new chapter for R
- Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512 for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-positive-topline-results-from-phase-3-comet-trials-of-ar-15512-a-novel-topical-drug-candidate-for-dry-eye/2482063/Alcon announced positive topline results from the two pivotal phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both COMET-2 and COMET-3, which enrolled more than 93
- Zenni Optical Announces 2023 Eye Care Access Scholarship Winnershttps://modernod.com/news/zenni-optical-announces-2023-eye-care-access-scholarship-winners/2482062/Zenni Optical has awarded five optometry students with its 2023 Eye Care Access Scholarship. Now in its second year, the Zenni Eye Care Access Scholarship recognizes incoming students who want to provide eye care to communities in need everywhere.
- Aviceda Announces Topline Data From Part 1 of the Phase 2/3 SIGLEC Trial of GA Drug Candidate AVD-104https://modernod.com/news/aviceda-therapeutics-announces-topline-data-from-part-1-of-the-phase-23-siglec-clinical-trial-for-avd-104-demonstrating-positive-safety-and-early-clinical-efficacy-in-patients-with-geographic-atrophy/2482061/Aviceda Therapeutics announced positive topline data of part 1 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), showing positive safety and efficacy outcomes which were observed at 3 months after a single
- Alkeus’ Gildeuretinol Studied to Halt Progression of Early-Stage Stargardt Diseasehttps://modernod.com/news/alkeus-gildeuretinol-studied-to-halt-progression-of-early-stage-stargardt-disease/2482055/Alkeus Pharmaceuticals announced positive interim data showing gildeuretinol halted Stargardt disease progression for up to 6 years in the ongoing TEASE-3 clinical trial. The first three teenage patients with early-stage Stargardt disease enrolled in the trial and treated with oral gild
- Harrow Launches Dry Eye Drug Vevye in the United Stateshttps://modernod.com/news/harrow-introduces-vevye-in-united-states-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2482053/Harrow announced that Vevye (cyclosporine ophthalmic solution) 0.1% is now available in the United States. It is indicated for treating the signs and symptoms of dry eye disease (DED). Vevye is the company’s nonpreserved, twice-daily dosed prescription drug based on a water free s